Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
3.47 (CAD) • At close October 17, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Eupraxia Pharmaceuticals Inc. |
Symbool | EPRX.TO |
Munteenheid | CAD |
Prijs | 3.47 |
Beurswaarde | 123,610,422 |
Dividendpercentage | 0% |
52-weken bereik | 3.1 - 7.64 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. James A. Helliwell FRCPC, M.D. |
Website | https://www.eupraxiapharma.com |
An error occurred while fetching data.
Over Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CAD)
Cijfers zijn in miljoenen (CAD)